Aurobindo acquires four biosimilar products from TL Biopharmaceutical

February 10, 2017 11:25 AM


Aurobindo Pharma Limited has announced the acquisition of four cell culture derived biosimilar products from TL Biopharmaceutical AG.

As part of this agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally. The branded market size of these four biosimilars, three of them monoclonal antibodies in oncology is “very promising”, Aurobindo said and added that regulatory filing for these products is intended in the period 2020-22.

The company is preparing to take its lead molecule from this transaction, a bevacizumab biosimilar, for clinical trials in 2017. Bevacizumab (Avastin) is an anti-antiogenesis drug used in treating multiple-cancers including metastatic colon or rectal cancer, non-squamous and non-small cell lung cancers.

“This transaction is a strategic investment for future growth and will position Aurobindo as a strong player in the rapidly evolving biosimilars landscape. Building on these first four products licensed from TL, Aurobindo is expanding its diverse portfolio of eight more next wave of biosimilars,” the company said.

Aurobindo has set up a fully functional R&D center for biologics development and is also establishing a state-of-art manufacturing facility in Hyderabad, Telangana.

Source: Aurobiondo Pharma

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!